Delivery Order SPE2DB22D2206-SPE2DB25FJA84
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,277.78 to AmerisourceBergen Drug Corp for OMNIPOD 5 DEXG7G6 Pods (Generation 5) 5-unit supplies. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition based on merit and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,715.24 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 insulin infusion pump pods (Generation 5) with a completion date of August 28, 2025. This non-competed delivery order utilizes firm fixed pricing and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is positioned as a critical vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,876.41 to AmerisourceBergen Drug Corp for the OMNIPOD 5 DEXG7G6 INTRO (GEN 5)S on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a product delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $17,251.15 to AmerisourceBergen Drug Corp for OmniPod 5 continuous glucose monitoring pods (Generation 5) with a completion date of September 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The OmniPod system represents a critical medical device for diabetes management,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,926.33 to AmerisourceBergen Drug Corp for OmniPod 5 DEXG7G6 Pods (Generation 5) 5S, medical devices used in diabetes management. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, utilizes firm fixed pricing and was awarded on a competitive basis without a set-aside designation. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $6,381.97 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 DEXG7G6 Pods (Gen 5) 5S, a diabetes management device. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order was placed on July 18, 2025, with an ultimate completion date of July...
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a $1,372.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 pods on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under the company's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $9,190.25 to AmerisourceBergen Drug Corp on September 4, 2025, for OmniPod 5 Dexcom G7 insulin delivery pods (Generation 5), with a completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical and medical device supplier to the federal government. The delivery will be fulfilled from the vendor's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $36,377.71 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 insulin infusion pump pods. This firm fixed-price delivery order was competitively awarded without a set-aside designation and carries an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJA84Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,285.84 to AmerisourceBergen Drug Corp for OMNIPOD 5 DEXG7G6 pods (Generation 5) with a firm fixed price contract type. This non-competitive delivery order was executed on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The OMNIPOD 5 represents an advanced diabetes management medical device, reflecting DLA's ongoing procurement of specialized healthcare commodities for military and federal healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying pharmaceutical products, vaccines, and specialized medical devices across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's selection demonstrates its established capability to fulfill federal medical supply requirements within DLA's comprehensive global pharmaceutical support framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 7/23/25 |